Headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.9278734594295 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media headlines that may have impacted Accern’s scoring:

Spectrum Pharmaceuticals (NASDAQ SPPI) traded down $0.23 during mid-day trading on Thursday, hitting $20.50. 45,548 shares of the stock traded hands, compared to its average volume of 987,818. Spectrum Pharmaceuticals has a 1 year low of $5.00 and a 1 year high of $23.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.04 and a quick ratio of 4.89. The stock has a market capitalization of $2,112.90, a P/E ratio of -20.80 and a beta of 1.64.

SPPI has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $29.00 target price (up previously from $20.00) on shares of Spectrum Pharmaceuticals in a report on Wednesday, October 18th. Jefferies Group boosted their target price on shares of Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a report on Friday, October 20th. Guggenheim initiated coverage on shares of Spectrum Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $32.00 target price on the stock. B. Riley initiated coverage on shares of Spectrum Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $22.83.

ILLEGAL ACTIVITY NOTICE: “Spectrum Pharmaceuticals (SPPI) Earns Coverage Optimism Rating of 0.23” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/02/08/spectrum-pharmaceuticals-sppi-earns-coverage-optimism-rating-of-0-23.html.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Insider Buying and Selling by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.